Regeneron scores Eylea patent win against Mylan, keeping biosimilar at bay

Re­gen­eron pre­vailed in a ma­jor patent fight against My­lan, staving off biosim­i­lar com­pe­ti­tion for its flag­ship eye drug Eylea for an­oth­er few years.

The big biotech first sued My­lan in Au­gust 2022, claim­ing that a pro­posed copy of Eylea in­fringed on the 11,084,865 patent. My­lan had filed for FDA ap­proval in Oc­to­ber 2021. Among oth­er things, the ‘865 patent cov­ers an oph­thalmic for­mu­la­tion of a vas­cu­lar en­dothe­lial growth fac­tor (VEGF) an­tag­o­nist suit­able for in­trav­it­re­al ad­min­is­tra­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.